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Abstract. Peroxiredoxin (Prdx) proteins are thiol-specific 
antioxidants that protect cells from oxidative stress in many 
normal and disease states. There are six Prdx proteins 
expressed in mammals, each with a characteristic tissue 
expression, subcellular distribution and substrate specificity. 
Recent studies have revealed elevated Prdx levels in many 
cancers, suggesting a protective role for these proteins in 
cancer cell survival. The present study is the first to investi-
gate the function of all six Prdx proteins in the MCF-7 breast 
cancer cell line. We show that these cells have both higher 
resistance to doxorubicin-induced toxicity and significantly 
elevated Prdx levels, compared to the non-cancer MCF-10A 
cells. Using transient siRNA transfections, we show that 
Prdx3 suppression leads to decreased MCF-7 cell survival 
in the absence of doxorubicin. We further demonstrate that 
individual suppression of four of six of the Prdx proteins 
leads to increased doxorubicin-induced toxicity by apoptosis. 
Finally, we show that clonal selection of a doxorubicin-resis-
tant MCF-7 subline by 2-week culture in 0.1 µM doxorubicin 
resulted in a marked elevation in the expression of several 
Prdx proteins. Together, these data reveal a protective func-
tion for peroxiredoxins in MCF-7 cell survival, and suggest 
that Prdx overexpression in breast cancer may play a role in 
doxorubicin-resistance in these, and possibly other, breast 
cancer cells. This study is the first to investigate the function 
of the entire Prdx family in a breast cancer cell line.
Introduction
The peroxiredoxins (Prdxs) are a ubiquitous family of 
evolutionarily conserved antioxidant proteins that reduce 
aqueous and lipid peroxides associated with normal 
metabolism (1-3). There are six members of the mammalian 
peroxiredoxin family, which can be subdivided into three 
classes: the 2-Cys Prdxs (Prdx1-4), the atypical 2-Cys Prdx 
(Prdx5) and the 1-Cys Prdx (Prdx6). These proteins reduce 
cellular substrates by converting their active-site cysteines 
to sulfenic acid, which can be re-reduced by thiols such as 
ascorbic acid or glutathione through different mechanisms 
for different classes. These proteins are highly abundant 
in mammalian cells, suggesting an important role in anti-
oxidant defense. In addition, peroxiredoxins participate in 
redox-sensitive signal transduction pathways, and are know 
to have effects on cell growth, proliferation, differentiation 
and apoptosis (4,5).
It has long been recognized that cancer cells harbor 
elevated levels of highly reactive oxygen species (ROS) 
such as hydrogen peroxide and superoxide (6,7), exhibiting 
many signs of an oxidatively stressed environment. There 
is evidence that this oxidative stress may be a factor in both 
cancer initiation and/or cancer progression, depending on 
the tumor (8). Unlike normal cells, which are susceptible to 
cytotoxicity from such high levels of ROS, cancer cells are 
relatively resistant and can evade cell death, yet the precise 
mechanisms are not clear. Over the past several years, studies 
have reported overexpression of Prdxs in several types of 
cancer (9-14), and there is mounting evidence that Prdxs 
play a role in carcinogenesis (9,15-19). These data suggest 
that cancer cell resistance to ROS may be provided, at least 
in part, through peroxiredoxin overexpression, leading to 
increased antioxidant activity and/or alteration in key redox-
regulated growth and death pathways. However, there is very 
little understanding of the precise role peroxiredoxins play 
in this protection or the mechanism that governs increased 
peroxiredoxin expression in cancer cells.
Many studies have reported that breast tumors exhibit 
elevated levels of Prdxs compared to normal breast epithelial 
tissue (10,12,16,20). Furthermore, based on evidence that an 
adaptive oxidative stress response is critical to chemore-
sistance, it was recently suggested that peroxiredoxins are 
likely to be key players in chemoresistance in breast cancer, 
and may be potential targets for intervention (21). While 
clinical studies are important, a comparison of relevant cell 
lines can be a valuable tool in understanding the role of Prdxs 
in breast cancer biology and drug resistance. We and others 
have shown significant overexpression of Prdxs in the MCF-7 
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adenocarcinoma cell line, as compared to the non-cancerous 
MCF-10A breast epithelial line (22-24). We previously 
demonstrated that MCF-7 cells are much more resistant to 
H2O2-induced apoptosis than the non-malignant MCF-10A 
breast cells (22). Bae et al also reported elevated Prdx levels 
in MCF-7 cells, and went on to show that overexpression of 
either Prdx1 or Prdx2 in MCF-10A cells conferred resistance 
to H2O2-induced apoptosis (22). Furthermore, radiation-
resistant lines derived from the MCF-7 cells have elevated 
Prdx2 levels, and Prdx2 suppression in these cells partially 
reversed the radiation resistance (25). Taken together, these 
studies suggest a protective role for Prdxs in breast cancer 
and suggest that use of these cell lines may be an important 
tool in understanding the function of Prdxs in breast cancer.
Based on these data and implications, we sought to 
examine the role of Prdxs in MCF-7 cell survival and doxo-
rubicin-resistance using siRNA-mediated protein suppression. 
Doxorubicin is an anthracycline antibiotic that has been used 
as an effective chemotherapy agent in the treatment of breast 
cancer in patients, although many patients develop resistance 
to the drug leading to aggressive relapse (26). Doxorubicin 
induces oxidative stress and apoptosis in MCF-7 cells (27), 
suggesting that antioxidants may be an important line of 
defense in this and other breast cancer cells. We hypothesized 
that Prdx suppression in MCF-7 cells would decrease the 
viability of these cells and increase their susceptibility to 
doxorubicin-induced toxicity. Likewise, we hypothesized that 
prolonged exposure of MCF-7 cells to doxorubicin would lead 
to induction of Prdx expression.
Materials and methods
Cell culture. MCF-7 cells were cultured in ATCC-formulated 
Eagle's minimum essential medium containing bovine insulin 
(0.01 mg/ml) and 10% fetal bovine serum. MCF-10A cells 
were cultured in MEBM medium, supplemented with BPE 
(13 mg/ml), hydrocortisone (0.5 mg/ml), hEGF (10 µg/ml), 
insulin (5 mg/ml), and cholera toxin (100 ng/ml). Both cell lines 
were cultured at 37˚C in a humidified 5% CO2 atmosphere.
Doxorubicin treatments. To determine resistance to doxoru-
bicin, MCF-7 and MCF10-A cells were cultured in 48-well 
plates and treated the following day with 0.1 or 0.5 µM doxo-
rubicin for 48 h. To determine the effect of Prdx suppression 
on doxorubicin-resistance, MCF-7 cells were allowed to grow 
for 48 h after siRNA transfection and then were treated with 
0.5 µM doxorubicin for an additional 24 h. For generation of 
a doxorubicin-resistant culture, MCF-7 cells were subcultured 
for 14 days in T-75 flasks in the presence of 0.1 µM doxoru-
bicin, with media and treatment replacement every 3-4 days.
Measurement of viable cell density. Cell viability was 
determined using an MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide assay. MCF-7 and MCF-10A cells 
were seeded into separate 48-well plates in replicate groups 
of four and transfection/treatment experiments conducted. 
After treatment incubation, cells were assayed for MTT at a 
confluency less than 80%. Cells were rinsed with phenol red-
free medium and incubated with 0.5 mg/ml MTT (diluted in 
phenol red-free medium) for 1.5 h at 37˚C. This medium was 
then removed and replaced with 200 µl of acidic isopropanol 
and the plate was rocked for 5 min at room temperature. The 
absorbance of the solubilized product was read at 570 nm 
using the corresponding absorbance of cell-free wells or the 
absorbance at 650 for background subtraction.
Suppression of Prdx1-6 by siRNA. MCF-7 cells were seeded 
into 24-well plates at 50,000 cells per well. Twenty-four hours 
after seeding, cells were transfected using Silencer Select 
siRNA (Ambion, Austin, TX, USA) for Prdx1-6 (or a nega-
tive control siRNA) at a final concentration of 33 nM using 
the Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, 
USA). The siRNA ID#s are as follows: Prdx1 (s10007), Prdx2 
(s13959), Prdx3 (s21507), Prdx4 (s20686), Prdx5 (s24559), 
and Prdx6 (s18429). Briefly, for each well 20 pmoles of 
siRNA was mixed with 1 µl Lipofectamine 2000 reagent and 
98 µl Opti-MEM I serum-free media (Invitrogen), allowed 
to precipitate for 20 min, and subsequently added to wells. 
Transfected cells were cultured for 48 h followed by protein 
extraction and western blot analysis to determine levels of 
Prdx suppression. Transfected cells used for cell viability and 
toxicity assays were treated with or without doxorubicin for an 
additional 24 h prior to end-point assays.
Western blot analysis. For protein analysis, cells were 
lysed in mammalian protein extraction reagent (MPER) 
(Thermo Scientific, Waltham, MA, USA) according to the 
product suggestions. Protein was quantified using the Coomassie 
Blue Protein Assay Reagent (Bio-Rad, Hercules, CA, USA), 
and lysates were separated on a 12% Mini Protean TGX gel 
and electrophoretically transferred on to an ImmunBlot PVDF 
membrane (Bio-Rad). Blots were blocked and incubated with 
primary antibodies from Abcam [anti-Prdx1 (ab59538), anti-
Prdx2 (ab15572), anti-Prdx3 (ab16751), anti-Prdx4 (ab59542), 
anti-Prdx5 (ab16944) anti-Prdx6 (ab16947); Cambridge, MA, 
USA]. An antibody for GAPDH (Sigma, St. Louis, MO, 
USA) was used as a loading control. Blots were subsequently 
processed with the appropriate secondary antibody and chemi-
luminescent CDP-Star Reagent, and imaged with X-OMAT 
film (Kodak). Bands were quantified using Image J software.
Measurement of cytotoxicity. Cytotoxicity was determined 
by the indirect measurement of lactate dehydrogenase (LDH) 
activity using the Cytotox 96 Assay (Promega, Madison, WI, 
USA). Cells were transfected as described above and cultured 
for 48 h. To measure released LDH, cell medium was removed 
and 40 µl was assayed using an equal volume of substrate mix 
and processed according to manufacturer's recommendations. 
Absorbance was measured at 490 nm and absorbance of media 
blanks (with no cells) was subtracted from each value.
Measurement of apoptosis. A membrane permeability/ 
dead cell apoptosis kit (Invitrogen) and Hoechst 33342 
(Life Technologies) were used to detect cell death. Cells were 
transfected according to the previous methods and treated with 
or without 0.5 µM doxorubicin for 24 h. Cells were stained with 
1 µl/ml Yo-Pro and 1 µg/ml Hoechst dye and photographed 
using phase contrast and fluorescence microscopy. The field of 
view was quantified as a percent of cells staining positive for 
Hoechst and Yo-Pro.
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Statistical analysis. The means of individual treatment groups 
in each quantitative experiment were statistically compared 
using a two-tailed Student's t-test, assuming equal variances.
Results
We first compared the non-cancerous MCF-10A cell line 
with the MCF-7 breast adenocarcinoma for sensitivity to 
doxorubicin-induced toxicity. As shown in Fig. 1, MCF-10A 
cells exhibited an approximately 50% reduction in viable cells 
after 24 h with 0.1 µM doxorubicin, as compared to untreated 
cells, and a nearly 80% reduction with 0.5 µM doxorubicin. 
In contrast, MCF-7 cells exhibited only a 10 and 20% reduc-
tion in viability with the same treatments, respectively. The 
data show significant tolerance of the MCF-7 cell line to this 
drug treatment. Analysis of peroxiredoxin protein expression 
in these two lines revealed that expression of five of the six 
Prdx proteins (Prdx1-5) are markedly elevated in MCF-7 cells, 
as compared to MCF-10A cells (Fig. 2). Together, these data 
show a correlation between doxorubicin resistance and perox-
iredoxin expression in MCF-7 cells.
In order to address the potential role of Prdxs in MCF-7 
cell survival, we used transient siRNA transfection experi-
ments to suppress individual Prdx proteins in these cells. 
Cells were transfected with 33 nM siRNA and Prdx levels 
measured after 48 h by western blot analysis. As shown in 
Fig. 3A, we were able to greatly reduce the expression of all 
six Prdx proteins by this method. Quantification of these levels 
is shown in Fig. 3B, which demonstrates a range between 70 
and 90% protein suppression relative to cells transfected with 
a negative control siRNA.
Before examining the effect of Prdx suppression on doxo-
rubicin sensitivity, we determined whether Prdx suppression 
in these cells affected their morphology or viability. Seventy- 
two hours after transfection (and 24 h after suppression was 
measured by western blot analysis) the cells were examined 
by phase contrast microscopy and analyzed for cytotoxicity 
using the released LDH assay. First, we found no difference 
in either morphology or cytotoxicity between untransfected 
cells and those transfected with negative control siRNA (data 
not shown). The only morphological change observed in trans-
fected cells was with Prdx3. While negative-control transfected 
cells appear to have a normal cobblestone-like appearance 
(Fig. 4A), Prdx3-transfected cells are significantly smaller 
and rounder (Fig. 4B). In addition, there were fewer cells in 
all Prdx3-transfected replicate wells. Likewise, cytotoxicity 
was significantly increased in Prdx3-transfected cells in the 
absence of doxorubicin treatment, relative to cells transfected 
with negative control siRNA (Fig. 4B). No other transfection 
condition showed an effect. Together, these data show that 
Prdx3 suppression renders MCF-7 cells more susceptible to 
death in the absence of doxorubicin, suggesting an important 
role for this protein in the general viability of these cells.
To examine the effect of Prdx suppression on doxorubicin 
sensitivity, 48 h after transfection cells were treated with 
0.5 µM doxorubicin for 24 h, viable cell number was measured 
using the MTT assay, which was originally used to compare 
doxorubicin sensitivity in the cancerous and non-cancerous 
cell lines. As shown in Fig. 5A, doxorubicin treatment led to a 
Figure 1. MCF-7 cells are relatively resistant to doxorubicin-induced toxicity. 
MCF-7 and MCF-10A cells were cultured under normal growth conditions 
and seeded into the well plates. Cells were treated for 48 h with 0, 0.1 or 
0.5 µM doxorubicin and viable cells quantified using the MTT assay. An 
average from six replicates for each treatment (± SD) is shown. (p<0.005 for 
MCF-10A treatments vs. control; p<0.05 for MCF-7 treatments vs. control.)
Figure 2. MCF-7 cells express elevated levels of Prdx proteins. MCF-7 and 
MCF-10A cells were cultured under normal growth conditions. Cells were lysed 
and Prdx expression measured by western blot analysis. GAPDH expression 
was used as a loading control.
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significant reduction in MTT absorbance in cells transfected 
with either Prdx1, Prdx2, Prdx3 or Prdx5. The magnitude of 
this decrease was about 40% for Prdx1 and Prdx2, and over 
50% for Prdx3 and Prdx5. These data suggest that reduction 
in the levels of these Prdx proteins in MCF-7 cells inhibits 
growth and/or induces death in response to doxorubicin treat-
ment. We attempted to address this by measuring cell death 
using the Hoechst/Yo-Pro cell staining method. Representative 
phase contrast and fluorescent images are shown for doxoru-
bicin-treated cells transfected with negative control siRNA, or 
one of the Prdxs that showed an MTT reduction. A reduced cell 
number in all Prdx-transfected cells, compared to the negative 
control, was observed. These data are consistent with the MTT 
data. Analysis of the stained cells shows a marked increase in 
the percentage of dead cells in all Prdx-transfected conditions. 
These data strongly suggest that suppression of Prdx1, Prdx2, 
Prdx3 and Prdx5 in MCF-7 cells increases the susceptibility of 
MCF-7 cells to doxorubicin-induced cell death.
Since our data suggested a role for Prdxs in doxorubicin 
resistance in MCF-7 cells, we asked whether long-term treat-
ment of these cells and selection of a highly resistant subline 
would lead to a concomitant change in Prdx levels. This exper-
iment has important clinical significance since many breast 
cancers develop resistance with prolonged chemotherapy 
treatment. Cells were cultured in the presence of 0.1 µM doxo-
rubicin for 14 days and Prdx expression analyzed. As shown in 
Fig. 6A, 14 days of treatment led to a marked increase in the 
expression of Prdxs 2, 3, 4 and 5. Quantification of these levels 
Figure 3. Transient transfection of MCF-7 cells with Prdx siRNA markedly suppresses Prdx expression. MCF-7 cells were transfected with 33 nM negative 
control siRNA or specific Prdx siRNA and cultured for 48 h. Cells were lysed and Prdx expression measured by western blot analysis. Gapdh expression was 
used as a loading control. (A) Representative western blots showing expression in replicate transfections. (B) Protein expression was quantified from parallel 
experiments and normalized to GAPDH levels. Averages from replicate tranfections are shown (± SD).
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are represented in Fig. 6B, revealing a nearly 10X increase 
in Prdx2 expression, and an approximately 4-fold increase in 
levels of Prdx3, Prdx4 and Prdx5. It is clear from these data 
that culturing MCF-7 cells for 2 weeks in doxorubicin leads to 
a robust induction of several Prdx proteins.
Discussion
In the present study, we showed a correlation between doxo-
rubicin-resistance and peroxiredoxin levels between MCF-7 
and MCF-10A cells, demonstrating significantly higher resis-
tance and Prdx expression in the cancer line. Using transient 
transfections of MCF-7 cells with siRNA, we obtained marked 
reduction in Prdx levels for all six proteins, leading to moderate 
toxicity in Prdx3-suppressed cells. Subsequent treatment of 
siRNA-transfected cells with doxorubicin resulted in a reduc-
tion in viable cell number with suppression of either Prdx1, 
Prdx2, Prdx3 and Prdx5. We went on to show that this cell 
loss was, at least in part, due to apoptotic death. Finally, we 
demonstrated that 2-week treatment of MCF-7 cells with doxo-
rubicin leads to a marked induction of several Prdx proteins. 
Together, these data support our hypothesis that Prdxs play a 
protective role in MCF-7 cells and that doxorubicin-treatment 
leads to selection of drug-resistant cells that possess elevated 
Prdx levels.
We and others previously reported the overexpression of 
Prdxs in MCF-7 cells (22-24), which is consistent with elevated 
Prdx levels found in breast cancer tissue from patients. However, 
the mechanism by which these cells upregulate Prdxs is not 
understood. The Prdx family is inducible by oxidative stress 
in several systems, and ROS-induced modifications include 
regulation at both the transcriptional and post-transcriptional 
levels (4). A previous study from our lab showed that Prdxs1-5 
are elevated at the mRNA level in these cells, compared to 
MCF-10A cells, suggesting a transcriptional mechanism (24), 
but the signal transduction events and transcription factors 
mediating higher basal levels are not known. However, there 
is evidence that Nrf2 coordinately regulates the Prdx gene 
family in macrophages (28), so we are currently investigating 
this as a possible mechanism in MCF-7 cells.
Prdx suppression in many cells, including several cancer 
cell types, is known to increase cell death. Our results suggest 
a similar protective role for Prdx3 in MCF-7 cells, in the 
absence of any added oxidative stress. Prdx3 is a mitochondrial 
Figure 4. Prdx3 siRNA increases cytotoxicity in MCF-7 Cells. MCF-7 cells were transfected with 33 nM negative control siRNA or specific Prdx siRNA 
and cultured for 48 h. (A) Cells were photographed with phase contrast microscopy. Representative images for control and Prdx3 transfected cells are 
shown. (B) Cytotoxicity was measured using the Released LDH assay. The average of six replicate wells for each treatment are shown (± SD). p<0.005 for 
Prdx3.
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peroxiredoxin that is transcriptionally regulated by c-myc and 
is required for proliferation, transformation, and apoptosis 
in ovarian cancer cells (29). Recently, a similar function was 
reported for Prdx3 in cervical cancer cells (30). From these 
and other studies, the importance of Prdx3 as a key protective 
protein in cancer is well established. Our results are the first 
to demonstrate this same function for Prdx3 in breast cancer 
cells, suggesting that this protein may have a more ubiquitous 
survival function in cancer.
We showed that MCF-7 breast cancer cells are significantly 
more resistant to doxorubicin-induced toxicity at both 0.1 and 
0.5 µM concentrations than the non-cancerous MCF-10A cells. 
Gajewski et al also demonstrated that MCF-10A cells exposed 
to 0.1 µM doxorubicin (a clinically relevant dosage) underwent 
growth arrest and apoptosis, and also developed elevated levels 
of ROS (31). However, our demonstration that siRNA-mediated 
Prdx suppression markedly increases doxorubicin-induced 
apoptosis is a novel finding, and one that is consistent with 
the known ROS-inducing action of doxorubicin as well as 
the increased susceptibility of Prdx-suppressed MCF-7 cells 
to ROS-induced apoptosis. For example, Wang et al showed 
that Prdx2 suppression in MCF-7 cells increased sensitivity to 
radiation-induced cell death (25), and a recent follow-up study 
demonstrated that this occurred by alterations in cellular thiol 
status and intracellular Ca2+ homeostasis (32). Likewise, Prdx1 
suppression in MCF-7 cells leads to apoptosis induced by 
β-lapachone, an anticancer agent that produces large amounts of 
ROS induced apoptosis (33). In addition, Bae et al showed that 
transgenic overexpression of Prdx1 and Prdx2 in MCF-10A cells 
increases their resistance to peroxide-induced cell death (22). 
Together, there is strong evidence for Prdxs as key protective 
players against ROS-induced death of breast cancer cells.
Figure 5. Effect of Prdx suppression on doxorubicin-induced toxicity. MCF-7 cells were transfected with 33 nM negative control siRNA or specific Prdx 
siRNA, cultured for 48 h, and treated for 24 h with 0.5 µM doxorubicin. (A) Viable cells were quantified using an MTT assay. Formazan absorbance at 570 
was measured for each well, with A650 used for background subtraction. Averages of six replicate wells are shown (± SD). *p<0.005. (B) Apoptosis was 
measured in separate wells using Hoechst/Yo-Pro staining and cells were photographed with phase contrast and fluorescence microscopy. Representative 
images for transfectants showing a significant decrease in MTT levels (Prdx1, Prdx2, Prdx3 and Prdx5) are shown.
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Our results further showed a functional relationship 
between Prdx expression and doxorubicin resistance using 
a prolonged doxorubicin treatment. The marked induction 
of several Prdx proteins after a 2-week culture with 0.1 µM 
doxorubicin suggests higher levels in drug-resistant cells. 
While it is not clear that this Prdx induction is essential for 
clonal selection of resistant cells, this observation coupled 
with the data from our transfection experiments strongly 
suggests an important role for these proteins in cell survival. 
Interestingly, short-term (4 or 24 h) treatment of MCF-7 
cells with 0.1 or 0.5 µM doxorubicin does not alter Prdx 
levels (data not shown), suggesting that the changes in gene 
expression are likely associated with the selection of resis-
tant cells over time.
In conclusion, our data are the first to report an effect 
of doxorubicin treatment on Prdx expression in breast 
cancer cells, as well as a protective role for the peroxire-
doxin protein family in breast cancer cell resistance to 
doxorubicin. Since the innate and acquired resistance of 
many breast tumors to doxorubicin is of critical concern 
for patients, a better understanding of the mechanisms 
governing this likely multifactorial phenomenon is essen-
tial. While we do not yet understand the precise role of 
each individual Prdx in the basal antioxidant defense 
system in these cells, Prdxs may, in fact, play an essential 
role in the survival of breast cancer cells in vivo. Based 
on the abundance and obvious importance of this family 
of antioxidants in normal and cancer cell biology, and the 
critical role of oxidative stress in chemotherapy success, 
this area of research warrants further investigation and is 
likely to provide an important new avenue for new thera-
peutic interventions for the treatment of breast cancer.
Figure 6. Two-week culture of MCF-7 cells with doxorubicin induces Prdx expression. MCF-7 cells were cultured for 14 days in the presence of 0.1 µM doxo-
rubicin. Cells from these and control flasks were lysed and analyzed for Prdx expression using western blot analysis. GAPDH expression was used as a loading 
control. (A) A representative western blot showing expression in replicate treatments. (B) Protein expression was quantified and normalized against GAPDH levels.
McDONALD et al:  PEROXIREDOXIN FUNCTION IN BREAST CANCER CELL SURVIVAL AND CHEMORESISTANCE226
Acknowledgements
This study was supported in part by a grant from the 
Connecticut Breast Health Initiative (CTBHI).
References
 1. Fujii J and Ikeda Y: Advances in our understanding of perox-
iredoxin, a multifunctional, mammalian redox protein. Redox 
Rep 7: 123-130, 2002.
 2. Hofmann B, Hecht HJ and Flohe L: Peroxiredoxins. Biol Chem 
383: 347-364, 2002.
 3. Wood ZA, Schröder E, Harris JR and Poole LB: Structure, 
mechanism and regulation of peroxiredoxins. Trends Biochem 
Sci 28: 32-40, 2003.
 4. Immenschuh S and Baumgart-Vogt E: Peroxiredoxins, oxidative 
stress, and cell proliferation. Antioxid Redox Signal 7: 768-777, 
2005.
 5. Rhee SG, Chae HZ and Kim K: Peroxiredoxins: A historical 
overview and speculative preview of novel mechanisms and 
emerging concepts in cell signaling. Free Rad Biol Med 38: 
1543-1552, 2005.
 6. Halliwell B and Gutteridge J: Free Radicals in Biology and 
Medicine. 3rd edition. Oxford University Press, New York, NY, 
1999.
 7. Halliwell B: Oxidative stress and cancer: have we moved 
forward? Biochem J 401: 1-11, 2007.
 8. Valko M, Rhodes CJ, Moncol J, Izakovic M and Mazur M: Free 
radicals, metals and antioxidants in oxidative stress-induced 
cancer. Chem Biol  Interact 160: 1-40, 2006.
 9. Butterfield LH, Merino A, Golub SH and Shau H: From cyto-
protection to tumor suppression: the multifactorial role of 
peroxiredoxins. Antioxid Redox Signal 1: 385-402, 1999.
10. Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA and Chae HZ: 
Overexpression of peroxiredoxin in human breast cancer. 
Anticancer Res 21: 2085-2090, 2001.
11. Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, 
Kang SW, Rhee SG and Soini Y: Overexpression of peroxire-
doxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 
196: 316-323, 2002.
12. Karihtala, P, Mantyniemi A, Kang SW, Kinnula VL and 
Soini Y: Peroxiredoxins in breast carcinoma. Clin Cancer Res 
15: 3418-3424, 2003.
13. Lehtonen ST, Svensk AM, Soini Y, Paakko P, Hirvikoski P, 
Kang SW and Saily M: Peroxiredoxins, a novel protein family 
in lung cancer. Int J Cancer 111: 514-521, 2004.
14. Quan C, Cha EJ, Lee HL, Han KH, Lee KM and Kim WJ: 
Enhanced expression of peroxiredoxin I and VI correlates with 
development recurrence and progression of human bladder 
cancer. J Urolol 175: 1512-1516, 2006.
15. Kinnula VL, Paakko P and Soini Y: Antioxidant enzymes and 
redox regulating thiol proteins in malignancies of human lung. 
FEBS Lett 569: 1-6, 2004.
16. Li DQ, Wang L, Fei F, Hou YF, Luo JM, Wei-Chen, Zeng R, 
Wu J, Lu JS, Di GH, Ou ZL and Xia QC: Identification of breast 
cancer metastasis-associated proteins in an isogenic tumor 
metastasis model using two-dimensional gel electrophoresis 
and liquid chromatography-ion trap-mass spectrometry. 
Proteomics 6: 3352-3368, 2006.
17. Neumann CA and Fang Q: Are peroxiredoxins tumor 
suppressors? Curr Opin Pharm 7: 375-380, 2007.
18. Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di GH, Jin W, Ou ZL 
and Shen ZZ: Identification of the functional role of perox-
iredoxin 6 in the progression of breast cancer. Breast Cancer 
Res 9: R76, 2007.
19. Ishii T, Warabi E and Yanagawa T: Novel roles of peroxire-
doxins in inflammation, cancer and innate immunity. J Clin 
Biochem Nutr 50: 91-105, 2012.
20. Chahed K, Kabbage M, Hamrita B, Guillier CL, Trimeche M, 
Remadi S, Ehret-Sabatier L and Chouchane L: Detection of 
protein alterations in male breast cancer using two dimensional 
gel electrophoresis and mass spectrometry: The involvement 
of several pathways in tumorigenesis. Clin Chim Acta 388: 
106-114, 2008.
21. Coley HM: Mechanisms and strategies to overcome chemo-
therapy resistance in metastatic breast cancer. Cancer Treat Rev 
34: 378-390, 2008.
22. Bae J, Ahn S, Han W and Noh D: Peroxiredoxin I and II inhibit 
H2O2-induced cell death in MCF-7 Cell Lines. J Cell Biochem 
101: 1038-1045, 2007.
23. Goncalves K, Sullivan K and Phelan SA: Differential expression 
and function of peroxiredoxin 1 and peroxiredoxin 6 in 
cancerous MCF-7 and noncancerous MCF-10A breast epithelial 
cells. Cancer Invest 30: 38-47, 2012.
24. Tehan L, Taparra K and Phelan SA: Peroxiredoxin overex-
pression in MCF-7 breast cancer cells and regulation by cell 
proliferation and oxidative stress. Cancer Invest 31: 374-384, 
2013.
25. Wang T, Tamae D, LeBon T, Shively JE, Yen Y and Li JJ: The 
role of peroxiredoxin II in radiation-resistant MCF-7 breast 
cancer cells. Cancer Res 65: 10338-10346, 2005.
26. Hickman JA: Apoptosis induced by anticancer drugs. Cancer 
Metastasis Rev 11: 121-139, 1992.
27. Osbild S, Brault L, Battaglia E and Bagrel D: Resistance to 
cisplatin and adriamycin is associated with the inhibition of 
glutathione efflux in MCF-7-derived cells. Anticancer Res 26: 
3595-3600, 2006.
28. Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, 
Bannai S and Yamamoto M: Transcription factor Nrf2 coordi-
nately regulates a group of oxidative stress-inducible genes in 
macrophages. J Biol Chem 275: 16023-16029, 2000.
29. Wonsey DR, Zeller KI and Dang CV: The c-Myc target 
gene PRDX3 is required for mitochondrial homeostasis 
and neoplastic transformation. Proc Natl Acad Sci USA 99: 
6649-6654, 2002.
30. Li L, Zhang YG and Chen CL: Anti-apoptotic role of perox-
iredoxin III in cervical cancer cells. FEBS Open Bio 3: 51-54, 
2012.
31. Gajewski E, Gaur S, Akman SA, Matsumoto L, van Balgooy JNA 
and Doroshowa JH: Oxidative DNA base damage in MCF-10A 
breast epithelial cells at clinically achievable concentrations of 
doxorubicin. Biochem Pharmacol 73: 1947-1956, 2007.
32. Diaz AJG, Tamae D, Yen Y, Li JJ and Wang T: Enhanced 
radiation response in radioresistant MCF-7 cells by targeting 
peroxiredoxin II. Breast Cancer (Dove Med Press) 5: 87-101, 
2013.
33. He T, Banach-Latapy A, Vernis L, Dardalhon M, Chanet R 
and Huang ME: Peroxiredoxin 1 knockdown potentiates 
β-lapachone cytotoxicity through modulation of reactive 
oxygen species and mitogen-activated protein kinase signals. 
Carcinogenesis 34: 760-769, 2013.
